Echelon Biosciences was formed from a project under the Center for Cell Signaling, a State of Utah Center of Excellence, and was incorporated under the laws of the state of Utah as Echelon Research Laboratories, Inc. on October 3, 1997. The company has since changed its name to Echelon Biosciences Incorporated. The company was organized to further the science of lipid cell signaling and critical metabolic enzymes, which provide new and viable targets for the development of potential drugs and diagnostics for cancer, diabetes, inflammation, infections, and cardiovascular disease.
From 1997 through 2004 Echelon primarily used government grants and product sales revenues to fund its research efforts. In early 2005 Echelon was purchased by Aeterna Zentaris (NAS: AEZS) for its MEP antiinfectives, PI 3-Kinase small molecule program and catalog business.
In late 2007, Echelon was acquired by Frontier Scientific Inc. Frontier is based in Logan, Utah; specializing in Porphyrin and related compounds and Photo Dynamic Therapy. The new ownership allows expanded research and funding for many positive aspects for both Echelon and Frontier.
- Phosphoinositides & Derivatives
- Inositol Phosphates
- Isoprenoids & MEP
- HEME Pathway Intermediates
- Thiol-reactive Probes
- Enzyme Substrates
- Antibodies and Recognition Proteins
- Lipid Protein Interaction Tools
- Kinase Assays
- Phosphates Assays
- Hydrolase Assays
- Lipid Detection Assays
- Biomarker Assays